Skip to content

News

The Sooran Noroozi Sarcoma Research Award: Honoring Resilience

We are delighted to share that the incredible story of Sooran Noroozi’s resilience and the launch of the Sooran Noroozi Sarcoma Research Award has been prominently featured on Global News.
Read More

Polaris Phase III study now recruiting patients!

Join the New Polaris Clinical Trial – Phase III study now recruiting patients with Leiomyosarcoma! Discover cutting-edge treatments and contribute to advancing sarcoma research. Contact us for more information and
Read More

Advancing Innovations with CQDM Funding

CQDM announces funding for three cancer research projects, supported by the Québec government grant. These projects aim to enhance cancer treatment efficacy and reduce side effects. They include Theratechnologies’ platform
Read More

Join Our GIST Support Group

This group has been created by SaRC-Q to offer a space for sharing, support, and mutual assistance to all those living with GIST (Gastrointestinal Stromal Tumor) in Quebec and Canada.
Read More

TGCT Trials Now Recruiting Patients From Across Canada

Trials involving Tenosynovial Giant Cell Tumor (TGCT) in Canada now welcome participants from all regions across the country. If you would like to participate in these clinical trials, lodging and
Read More

Sisters Confront Osteosarcoma: A Journey Guided by Dr. Saleh

Montreal, January 26, 2024 – Driven by an extraordinary spirit, the Harding sisters, Cassandra and Katelyn, have faced the same rare cancer—Osteosarcoma—within months of each other. This rare form of
Read More

Insights into Radiation-Induced Sarcomas of the Breast

In a groundbreaking study, researchers led by Vanessa Di Lalla at McGill University have conducted a comprehensive review of Radiation-Induced Sarcomas (RISs) of the breast, offering valuable insights into a
Read More

Unveiling Two New Clinical Trials

We are thrilled to announce the initiation of two groundbreaking clinical trials, marking significant strides in the field of sarcoma research. These trials, Abbisko Pimicotimib and PEAK, hold promise in
Read More